Skip to content

Extending and Banding the Roux-en-Y Gastric Bypass

Extending and Banding the Roux-en-Y Gastric Bypass

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05357807
Acronym
UPGRADE
Enrollment
375
Registered
2022-05-03
Start date
2021-03-01
Completion date
2028-03-01
Last updated
2024-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid Obesity

Brief summary

The Roux-en-Y gastric bypass (RYGB) has proven to be an effective treatment for morbid obesity by reducing weight and comorbidities. Extending the pouch may improve weightloss without the increase of complications. Some patients regain weight after initially good weightloss. Placing a minimizer around the pouch may prevent weight regain.

Detailed description

The Roux-en-Y gastric bypass (RYGB) has proven to be an effective treatment for morbid obesity by reducing weight and comorbidities. Extending the pouch may improve weightloss without the increase of complications. Some patients regain weight after initially good weightloss. Placing a minimizer around the pouch may prevent weight regain. A prospective randomize controlled trial. Study population: alle patients undergoing RYGB are eligible for the study. inclusion criteria are BMI 35-40 kg/m2 with one or more obesity related comorbidities, or BMI \> 40 kg/m2 without any comorbidities. Intervention: Standard RYGB versus an extended pouch RYGB vs a banded-extended RYGB.

Interventions

PROCEDUREStandard RYGB

Roux-en-Y Gastric bypass

Roux-en-Y gastric bypass with an extended pouch

PROCEDUREBanded extended pouch RYGB

Roux-en-Y gastric bypass with a banded extended pouch

Sponsors

Rijnstate Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* All patients who are eligible for a primary RYGB

Exclusion criteria

* Bariatric surgery in medical history * Patients with a language barrier which may affect the compliance with medical advice * Patients with a disease not related to morbid obesity, such as Cushing or drug related. * Chronic bowel disease for example Crohn's disease or colitis Colitis. * Renal impairment (MDRD \<30) * Hepatic dysfunction (liver function twice the normal values) * Pregnancy during follow-up * Patients with treatment-resistant reflux symptoms.

Design outcomes

Primary

MeasureTime frameDescription
Percentage Total Body Weight Loss (%TBWL)3 years((preoperative weight - current weight) / (preoperative weight)) x 100%. Weight loss measured in kilograms

Secondary

MeasureTime frameDescription
BODY-Q: Quality of life after bariatric surgery3 yearsBODY-Q: Patient reporterd outcome measurement, The questionnaire measures three domains; health related quality of life, appearance and experience of healthcare. Each domain is composed of independently functioning scales. Each scale contains different statements, which can be scored on four levels ranging from totally disagree to totally agree or from never to always. The sum of levels ranging from 1 to 4 is the raw score of the different scales. This score can be converted into a Rasch Transformed score ranging from 0, worst score, to 100, best score.
BAROS: Quality of life after bariatric surgery3 yearsBAROS; evaluates the results of obesity treatments by analyzing 3 domains: weight loss, changes in co-morbidities, and quality of life. Up to 3 points are allowed for each, and points are deducted for complications and reoperations. The final score classifies the results in 5 outcome groups, providing an objective definition of success or failure.
Percentage Excess Weight Loss (%EWL)3 years((Preoperative weight - current weight) / (preoperative weight - ideal weight at BMI 25)) x 100%. Weight loss measured in kilograms
Gastroesophageal reflux disease3 yearsGERD-HRQL questionnaire, a higher score on the questionnaire indicates more complaints of gastroesophageal reflux disease.
Change in comorbidities in patients pre- and postoperative3 yearsMeasuring reduction of diabetes, hypertension, dyslipidemia, osteoarticular disease, OSA
SF-36: Quality of life after bariatric surgery3 yearsSF-36; consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026